|
|
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Number of employees : 17 people.
|
|
|
| 2020 | | SEK (in Million) | % | | Biomarkers | 1.67 | 100% |
|
|
|
| 2020 | | SEK (in Million) | % | | United States | 1.25 | 74.7% | | European Union excluding Sweden | 0.397 | 23.8% | | Asia | 0.025 | 1.5% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
21,575,142 |
21,265,848 |
98.6% |
0 |
0.0% |
75.2% |
| Stock B |
0 |
6,698,230 |
0 |
0.0% |
0 |
0.0% |
|
|
|
| Name | Equities | % | | Coeli Asset Management AB | 1,170,082 |
5.50% | | Northern Light Management AB | 921,063 |
4.33% | | Gunnar Rylander | 572,112 |
2.69% | | Henrik Osvald | 564,106 |
2.65% | | Lars Erik Holmqvist | 503,630 |
2.37% | | LYM Consulting AB | 493,810 |
2.32% | | Anders Rylander | 379,756 |
1.79% | | Eccenovo AB | 300,000 |
1.41% | | East Capital Financial Services AB | 132,750 |
0.62% | | Norron AB | 109,762 |
0.52% |
|
| Company contact information |
|
Biovica International AB Dag Hammarskjölds väg 54B Uppsala Science Park Uppsala 752 37 Phone : +46.18.44.44.830 Fax : +46.18.57.24.28 Web : http://www.biovica.com |
|
|
Sector Bio Diagnostics & Testing
Connections : Biovica International AB (publ) |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
